Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02573896 · ClinicalTrials.gov registry record · Phase 1
Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells
A Phase 1 study of Neuroblastoma, sponsored by New Approaches to Neuroblastoma Therapy Consortium.
- Active
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 11
- Study locations
NCT02573896: Active Phase 1 study of Neuroblastoma, sponsored by New Approaches to Neuroblastoma Therapy Consortium.
NCT02573896 is a Phase 1 study of Neuroblastoma that is active but no longer recruiting, run by New Approaches to Neuroblastoma Therapy Consortium. The registered enrollment target is 13 participants, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (95% lower). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02573896, a Phase 1 study of Neuroblastoma, is active but no longer recruiting, sponsored by New Approaches to Neuroblastoma Therapy Consortium.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 11
- Study locations
Study Summary
This NANT trial will determine the maximum tolerated dose (MTD) of autologous expanded natural killer (NK) cells when combined with standard dosing of dinutuximab and will assess the feasibility of adding lenalidomide at the recommended Phase II dose of the expanded NK cells with dinutuximab, for treatment of children with refractory or recurrent neuroblastoma.
Primary Outcome
Proportion of patients whose NK cell product is at least 80% of 10\^7 NK cells per kg (sufficient cells to give at least 1 dose at the lowest dose level).
Conditions Studied
Interventions
- DRUG Lenalidomide
- DRUG Dinutuximab
- BIOLOGICAL NK Cells
Study Locations (11)
California
- Children's Hospital Los Angeles - Los Angeles
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Nationwide Children's Hospital - Columbus
Georgia
- AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus - Atlanta
Illinois
- University of Chicago Comer Children's Hospital - Chicago
Massachusetts
- Childrens Hospital Boston, Dana-Farber Cancer Institute. - Boston
Michigan
- C.S Mott Children's Hospital - Ann Arbor
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Texas
- Cook Children's Healthcare System - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-01-14 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What the registry record for NCT02573896 still lists
NCT02573896 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 3 interventions - of which Lenalidomide is the first listed.
NCT02573896 lists 11 locations in 9 states (California, Ohio, Georgia).
Frequently Asked Questions
What is clinical trial NCT02573896 about?
NCT02573896 is a clinical study titled "Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells". This NANT trial will determine the maximum tolerated dose (MTD) of autologous expanded natural killer (NK) cells when combined with standard dosing of dinutuximab and will assess the feasibility of adding lenalidomide at the recommended Phase II dose of the expanded NK cells with dinutuximab, for tr...
What is the current status of trial NCT02573896?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2019-01-14. Estimated completion is 2026-12.
What conditions does trial NCT02573896 study?
This clinical trial studies the following conditions: Neuroblastoma.
What interventions are being tested in trial NCT02573896?
The interventions under investigation include: Lenalidomide (DRUG), Dinutuximab (DRUG), NK Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT02573896?
This trial is sponsored by New Approaches to Neuroblastoma Therapy Consortium, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02573896 being conducted?
This trial has 11 study locations across California, Georgia, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02573896's enrollment target sits among peer trials
13 84th of 94 higher than 9 of 94 other Neuroblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
RECRUITING · Phase 1
-
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RECRUITING · Phase 1
-
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI